Regulator
The FDA cleared Dexter for more gynecology operations, including pelvic-organ prolapse repair and endometriosis surgery: its fourth US clearance.
A regulator's decision · Company-reported · Sets Dexter's stage
What the source says
“This marks the second clearance for Dexter in gynecology and the system's fourth overall.”
What it means
Dexter, from Distalmotion, is at stage 5 of 5 on our ladder: regulator-cleared or mass market. This event is one of the milestones that placed it there. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: Our sources report it working without human help.
More on Dexter
- Distalmotion raised $150 million, led by Revival Healthcare Capital, to grow US sales. In January 2026 Johnson & Johnson's venture arm also invested an undisclosed amount.
- The FDA cleared Dexter for hysterectomy (removal of the womb) through the 510(k) route.
- AdventHealth, which runs 50 hospitals in nine states, bought several Dexter robots: the company's first multi-robot sale in the US.
- The FDA cleared Dexter for gallbladder removal through the 510(k) route.
- Surgeons at UC San Diego Health did the first two US outpatient operations with Dexter, both hernia repairs.
- The FDA cleared Dexter through the De Novo route (DEN230084) for groin (inguinal) hernia repair in adults. More than 1,300 patients had already been treated with it in Europe.